In ccRCC, as a well-known target of HIF-2α, VEGFA also played a vital role in angiogenesis and was a key target of anti-cancer therapeutic agents (Garje et al., 2018; Meléndez-Rodríguez et al., 2018). The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.